Johannes Fröhlich

Johannes Fröhlich is a Professor and Chair of Organic Chemistry at Technische Universität Wien (TU Wien), where he also served as Vice Rector for Research (2011–2015) and Vice Rector for Research and Innovation (2015–2019). He was previously Dean of the Faculty of Technical Chemistry and Head of the Institute of Applied Synthetic Chemistry.

His research focuses on bioactive compounds, metabolomics, and organic electronics. He is a co-inventor of a patented synthetic method for Galanthamine, an Alzheimer's drug marketed as Reminyl® by Janssen Pharmaceuticals. His work bridges pharmaceutical chemistry and materials science, contributing to both therapeutic development and functional organic materials.

The recent publications (2010, 2014–2025) reflect a sustained interdisciplinary focus on organic synthesis, drug discovery, metabolite analysis, and organic electronic materials, with strong emphasis on industrial and medical applications.

Scientific Affiliations and Roles:

• Guest Professor at STU Bratislava, Masaryk University Brno, TU Dresden, and Heidelberg University
• Member, Management Committee and Administration Council of the European Chemistry Thematic Network (EU level)

Prof. Fröhlich has led major academic and research initiatives, including directing institutes and shaping research policy as Vice Rector. His leadership spans education, research innovation, and European collaboration. He has supervised students and researchers in synthetic organic chemistry, though specific advisees are not listed.

He is involved in advanced research projects related to pharmaceutical synthesis, metabolomics platforms, and organic electronic materials, likely supported by national and EU grants, though specific funding details are not provided.